drugset / Trial / NCT04270669
Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with wet age-related macular degeneration by multiple administration.
Timeline
- Start
- 2020-04-15
- Primary completion
- 2021-10-29
- Completion
- 2021-10-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RC28-E | Protein / enzyme biologic | 0.5 mg | Intravitreal |
| Subject | RC28-E | Protein / enzyme biologic | 1 mg | Intravitreal |
| Subject | RC28-E | Protein / enzyme biologic | 2 mg | Intravitreal |